These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16802166)

  • 1. Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes.
    Bomsien S; Aderjan R; Mattern R; Skopp G
    Eur J Clin Pharmacol; 2006 Aug; 62(8):639-43. PubMed ID: 16802166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An in vitro approach to potential methadone metabolic-inhibition interactions.
    Bomsien S; Skopp G
    Eur J Clin Pharmacol; 2007 Sep; 63(9):821-7. PubMed ID: 17598095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
    Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1.
    Bu HZ; Magis L; Knuth K; Teitelbaum P
    Rapid Commun Mass Spectrom; 2001; 15(10):741-8. PubMed ID: 11344532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.
    Polasek TM; Sadagopal JS; Elliot DJ; Miners JO
    Eur J Clin Pharmacol; 2010 Mar; 66(3):275-83. PubMed ID: 20012430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors.
    Filppula AM; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2014 Jul; 42(7):1202-9. PubMed ID: 24713129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways.
    Picard N; Cresteil T; Djebli N; Marquet P
    Drug Metab Dispos; 2005 May; 33(5):689-95. PubMed ID: 15743975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
    Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
    Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
    Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
    J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail.
    Sevior DK; Hokkanen J; Tolonen A; Abass K; Tursas L; Pelkonen O; Ahokas JT
    Xenobiotica; 2010 Apr; 40(4):245-54. PubMed ID: 20218935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes.
    Chang Y; Moody DE
    Eur J Clin Pharmacol; 2005 Feb; 60(12):875-81. PubMed ID: 15657781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.
    Moody DE; Liu F; Fang WB
    J Anal Toxicol; 2015 Jun; 39(5):374-86. PubMed ID: 25868557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatase is the major enzyme metabolizing buprenorphine in human placenta.
    Deshmukh SV; Nanovskaya TN; Ahmed MS
    J Pharmacol Exp Ther; 2003 Sep; 306(3):1099-105. PubMed ID: 12808001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
    Jaakkola T; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):44-51. PubMed ID: 16867170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis.
    Atkinson A; Kenny JR; Grime K
    Drug Metab Dispos; 2005 Nov; 33(11):1637-47. PubMed ID: 16049126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
    He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
    Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
    Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
    Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
    Kajosaari LI; Jaakkola T; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2006 Mar; 62(3):217-23. PubMed ID: 16447051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4.
    Kobayashi K; Yamamoto T; Chiba K; Tani M; Shimada N; Ishizaki T; Kuroiwa Y
    Drug Metab Dispos; 1998 Aug; 26(8):818-21. PubMed ID: 9698298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
    Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
    Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.